Levetiracetam Injection
Product Images NDC 43547-454

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 43547-454). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Solco Healthcare Us, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Image 01)

Chemical structure of levetiracetam showing a pyrrolidone ring attached to an ethyl group and an amide functional group, consistent with the active ingredient levetiracetam.*

FDA Label Image

Figure 1 (Image 02)

A vertical bar chart showing the percentage of patients for three groups: Placebo (7.4%), Levetiracetam 1,000 mg/day (37.1%), and Levetiracetam 3,000 mg/day (39.6%). The chart includes sample sizes for each group and notes statistical significance versus placebo.*

FDA Label Image

Figure 2 (Image 03)

A bar chart comparing the percentage of patients across three groups: placebo, Levetiracetam 1,000 mg/day, and Levetiracetam 2,000 mg/day. The y-axis represents percentage of patients, with values from 0% to 45%. Levetiracetam groups show higher percentages (20.8% and 35.2%) compared to placebo (6.3%), with statistical significance noted for both Levetiracetam doses versus placebo.*

FDA Label Image

Figure 3 (Image 04)

A bar graph depicting the percentage of patients for placebo and Levetiracetam 3,000 mg/day groups. The placebo group (N=104) shows 14.4% of patients, while the Levetiracetam group (N=180) shows 39.4%. An asterisk indicates the Levetiracetam value is statistically significant versus placebo.*

FDA Label Image

Figure 4 (Image 05)

A bar graph comparing the percentage of patients between two groups: Placebo (N=97) at 19.6%, and Levetiracetam (N=101) at 44.6%. An asterisk indicates a statistically significant difference versus placebo. The y-axis represents the percentage of patients.*

FDA Label Image

Figure 5 (Image 06)

Bar chart comparing the percentage of patients for Placebo (19.6%) and Levetiracetam (43.1%) groups. The y-axis shows percentage of patients from 0% to 45%. The Levetiracetam bar includes an asterisk indicating statistical significance versus placebo. The x-axis identifies the groups with sample sizes (Placebo N=51, Levetiracetam N=58).*

FDA Label Image

Figure 6 (Image 07)

A bar graph showing patient response rates comparing placebo and levetiracetam. The vertical axis denotes percentage of patients from 0% to 100%. The placebo group (N=84) shows a 45.2% response rate, while the levetiracetam group (N=79) shows a 72.2% response rate, with a notation indicating statistical significance versus placebo.*

FDA Label Image

Carton Label 1 (Image 08)

Label for Levetiracetam Injection USP, 500 mg/5 mL (100 mg/mL) intravenous injection by Solco Healthcare US, LLC. The package contains 10 single-dose 5 mL vials. The label indicates the product is for intravenous use only and must be diluted prior to administration.*

FDA Label Image

Vial Label 1 (Image 09)

Label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) single-dose vial. Distributed by Solco Healthcare US, LLC, Somerset, NJ 08873, USA. The label includes the product NDC 43547-454-41 and a barcode. Made in China.*

FDA Label Image

Carton Label 2 (Image 10)

Packaging label for LEVETIRACETAM Injection USP 500 mg/5 mL (100 mg/mL) by Solco Healthcare US, LLC. The label includes product name, strength, intravenous injection route, and instructions indicating it is for intravenous use only and must be diluted prior to administration. It lists manufacturer Zhejiang Huahai Pharmaceutical Co., Ltd and distributor Solco Healthcare US, LLC. The label also shows storage instructions, barcode, and revision date 03/2022.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.